Who founded ProteinQure?

ProteinQure was founded by Tomas Babej, Lucas Siow, Chris Ing, Mark Fingerhuth in 2017.

Who are ProteinQure's investors?

ProteinQure's investors include Golden Ventures, Intrepid Growth Partners, Kensington Capital Partners Limited, Felicis Ventures.

How much funding has ProteinQure raised?

ProteinQure has disclosed $11M raised across 1 of its 2 known rounds.

Where is ProteinQure headquartered?

ProteinQure is headquartered in Toronto, CA.

ProteinQure

Toronto, CA · Founded 2017 · 32 employees on LinkedIn · 5 known investors

Find your way into ProteinQure

899 people in our graph share verified history with the ProteinQure team — schools, employers, funds. One of them is your warm intro.

Bert Amatounlockedknows Tomas Babej · together at ProteinQure (overlapped)

knows the team · via Masaryk University

knows the team · via CDL-Toronto Quantum 2017/18

×9knows the team · via Creative Destruction Lab

ProteinQure is a clinical-stage biotech company that designs novel peptides for therapeutic delivery using its proprietary ProteinStudio computational platform powered by AI and molecular simulations. The company focuses on peptide-drug conjugates for tissue-specific and cell-specific delivery of therapeutics, with applications in oncology, renal disease, and blood-brain barrier transport.

AI & Machine Learning Biotech Deep Tech

Founders & leadership

ProteinQure was founded in 2017 by Tomas Babej, Lucas Siow, Chris Ing, and Mark Fingerhuth.

Tomas Babej Cofounder and Chief Technology OfficerTomas Babej studied theoretical computer science, machine learning, quantum computing, and cybersecurity at the university, and has contributed thousands of commits to open source projects including work with RedHat during his software engineering career. He is founder of ProteinQure, a biotech company developing a computational platform for protein therapeutic design.

Lucas Siow CEO - Co-FounderBefore starting the company in 2017, Siow spent five years at RBC Global Asset Management as a senior analyst and data scientist in investment policy, and worked a summer as a consultant at Boston Consulting Group. He now leads the team behind PQ203, a computationally designed peptide that has entered Phase I trials.

Chris Ing Chief Science Officer (CSO) - Co-Founder

Mark Fingerhuth Chief AI Officer (CAIO) - Co-FounderFingerhuth co-founded the company in 2017 and served as its first CEO until 2019, later sitting on its board and taking on the Chief AI Officer and scientific ML lead roles. Earlier, he co-founded the education startup Macademia, worked as lead software architect at Vitagen-X, and was an entrepreneur in residence at Creative Destruction Lab.

Investors · 5

Golden Ventureslisted by Golden VenturesToronto · $500K – $2.5M

How we know: Golden Ventures's portfolio page · funding news · biospace.com · Not right? Tell us

Intrepid Growth Partnerslisted by Intrepid Growth PartnersToronto

How we know: Intrepid Growth Partners's portfolio page · Not right? Tell us

Kensington Capital Partners Limitedlisted by Kensington Capital Partners LimitedToronto

How we know: funding news · gaebler.com · Not right? Tell us

Felicis VenturesreportedSan Francisco · $500K – $15M

How we know: funding news · Not right? Tell us

Also in the syndicate · 1

Heron Rock Fundlead

Funding

SEC filings, press & company announcements

$11M disclosed across 1 of 2 rounds · 2019–2025

$11MSeries AMay 2025 · 5 sources
Heron Rock Fund (lead), Golden Ventures, Kensington Capital, Kensington Capital Partners
Source ↗
Undisclosed amountseedJul 2019 · 2 sources
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

ProteinQure Raises Series A Financing to Advance First AI-Designed Peptide Therapeutic into Clinical Trialsfinance.yahoo.com · May 2025

ProteinQure Closes $11M in Series A Financingfinsmes.com · May 2025

ProteinQure Raises Series A Financing to Advance First AI-Designed Peptide Therapeutic into Clinical Trials - BioSpacebiospace.com · May 2025

Frequently asked questions

What does ProteinQure do?: ProteinQure is a clinical-stage biotech company that designs novel peptides for therapeutic delivery using its proprietary ProteinStudio computational platform powered by AI and molecular simulations. The company focuses on peptide-drug conjugates for tissue-specific and cell-specific delivery of therapeutics, with applications in oncology, renal disease, and blood-brain barrier transport.
Who founded ProteinQure?: ProteinQure was founded by Tomas Babej, Lucas Siow, Chris Ing, Mark Fingerhuth in 2017.
Who are ProteinQure's investors?: ProteinQure's investors include Golden Ventures, Intrepid Growth Partners, Kensington Capital Partners Limited, Felicis Ventures.
How much funding has ProteinQure raised?: ProteinQure has disclosed $11M raised across 1 of its 2 known rounds.
Where is ProteinQure headquartered?: ProteinQure is headquartered in Toronto, CA.